Page 42 - Bio Developments News Today

Biogen and Ginkgo Bioworks say their collaboration and license agreement will develop a next-generation AAV production platform, aiming to ‘redefine the industry standard for manufacturing recombinant adeno-associated virus (AAV)-based vectors’.

Sanofi and GSK announced today that their COVID-19 vaccine candidate demonstrated strong immune responses across all adult age groups in a Phase 2 trial. The investigational COVID-19 vaccine uses the same recombinant protein-based technology as one of Sanofi’s seasonal flu vaccines, along with GSK’s established pandemic adjuvant technology. The drug companies had hoped to have regulatory approval for their jab in the first half of this year, but interim results f...

A new agreement with Moderna will see Lonza add three more production lines at its site in Visp, Switzerland. Additional production lines will come online sequentially, said the contract development and manufacturing organization (CDMO). All three are expected to be operational in the earlier part of 2022 In May 2020, Lonza and Moderna announced a 10-year strategic collaboration agreement to enable the manufacture of Moderna’s COVID-19 vaccine and additional produ...

New preclinical research, published in Nature, suggests a new avenue for Alzheimer’s disease (AD) treatment, through restoring lymphatic flow in the brain

Moderna ramps up COVID-19 vaccine supply to 3 billion doses in 2022 Moderna has announced a set of additional investments to allow it to increase global supply of its COVID-19 vaccine. ‘We believe there will continue to be significant need for our vaccine into 2022 and 2023’, says the company. The company also expects to increase 2021 supply to between 800 million and 1 billion doses. Today’s announcement, alongside other news from fellow mRNA heavyweights Pfi...

Medicago has started a rolling submission with Health Canada for its plant-derived adjuvanted COVID-19 vaccine candidate: championing a unique and versatile platform that can also be scaled up easily. The tech – which the company has honed over years with its influenza vaccine candidate – uses plants to produce protein particles for the vaccine. If authorized, the COVID-19 vaccine will become the companys first commercial product. Plants as mini protein factories...

SparingVision acquires GAMUT Therapeutics; expanding novel ocular disease pipeline SparingVision will acquire GAMUT Therapeutics, the biotech behind a gene-independent approach to treat the later stages of rod-cone dystrophies such as retinitis pigmentosa (RP). GAMUT is a spin-out of the Institut de la Vision in Paris, focused on the research of scientific founder Dr. Deniz Dalkara and her collaborators. It was started in 2020 with seed funding from Advent France Bi...

Memorial Sloan Kettering (MSK) experts shared research findings in plenary talks during the American Association for Cancer Research’s (AACR) virtual meeting last week, with one talk reviewing the latest strategies for boosting the effectiveness of CAR T cell therapy. CAR T cell treatment, which has already been approved for some blood cancers, such as certain types of leukemia and lymphoma, is still not completely effective, even in some people who initially respo...

A UK study, which has been trialing the combination of Oxford-AstraZeneca and Pfizer vaccine doses, is now extending the program to include Moderna and Novavax vaccines.

Moderna to take mRNA flu and HIV vaccines into Phase 1 trials this year Moderna will take mRNA flu and HIV vaccines into Phase 1 trials this year, as well as beginning a pivotal Phase 3 study for its cytomegalovirus (CMV) vaccine candidate. A Phase 1 study for a RSV vaccine candidate is also under way. As part of its Vaccine Day this week, the company has updated its vaccine developement timeline and unveiled results from early stage mRNA vaccine trials. HIV vaccin...